Citadel Advisors’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-8,200
| Closed | -$1.35M | – | 15364 |
|
|
2021
Q2 | $1.35M | Sell |
8,200
-13,600
| -62% | -$2.27M | ﹤0.01% | 7560 |
|
|
2021
Q1 | $3.34M | Buy |
21,800
+6,000
| +38% | +$815K | ﹤0.01% | 5187 |
|
|
2020
Q4 | $1.98M | Buy |
+15,800
| New | +$1.77M | ﹤0.01% | 5371 |
|
|
2020
Q2 | – | Sell |
-5,400
| Closed | -$448K | – | 10808 |
|
|
2020
Q1 | $448K | Buy |
5,400
+1,600
| +42% | +$156K | ﹤0.01% | 6641 |
|
|
2019
Q4 | $422K | Sell |
3,800
-500
| -12% | -$51.4K | ﹤0.01% | 7077 |
|
|
2019
Q3 | $427K | Sell |
4,300
-12,000
| -74% | -$1.19M | ﹤0.01% | 7013 |
|
|
2019
Q2 | $1.62M | Sell |
16,300
-7,700
| -32% | -$735K | ﹤0.01% | 4888 |
|
|
2019
Q1 | $2.65M | Buy |
24,000
+5,000
| +26% | +$523K | ﹤0.01% | 3996 |
|
|
2018
Q4 | $1.75M | Sell |
19,000
-10,600
| -36% | -$1.07M | ﹤0.01% | 4367 |
|
|
2018
Q3 | $3.26M | Buy |
29,600
+17,900
| +153% | +$1.86M | ﹤0.01% | 3598 |
|
|
2018
Q2 | $1.09M | Buy |
11,700
+1,200
| +11% | +$103K | ﹤0.01% | 5060 |
|
|
2018
Q1 | $871K | Sell |
10,500
-700
| -6% | -$62.2K | ﹤0.01% | 5024 |
|
|
2017
Q4 | $1.02M | Buy |
11,200
+700
| +7% | +$58.2K | ﹤0.01% | 4620 |
|
|
2017
Q3 | $800K | Buy |
10,500
+1,500
| +17% | +$113K | ﹤0.01% | 4627 |
|
|
2017
Q2 | $675K | Buy |
+9,000
| New | +$624K | ﹤0.01% | 4690 |
|
Other funds holding PRAH
Citadel Advisors's PRAH Position: Q3 2021 in Review
Citadel Advisors sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 572,994 shares — an estimated $94.7M sold.
Citadel Advisors first reported a position in PRAH in Q1 2015 and held it in 23 quarters. The position peaked at $118M in Q3 2019. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Citadel Advisors reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Citadel Advisors sold 572,994 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $94.7M.
- Citadel Advisors first reported a position in PRA Health Sciences, Inc. in Q1 2015 and held it in 23 quarters.
- Citadel Advisors's PRA Health Sciences, Inc. position peaked at $118M in Q3 2019.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.